Not-for-profit organisation Stand Up To Cancer (SU2C) has formed a strategic alliance with US-based Lustgarten Foundation to support research to improve outcomes in patients with pancreatic cancer.

The Pancreatic Cancer Collective, funded by the Lustgarten Foundation and Stand Up To Cancer, will accelerate research for pancreatic cancer patients who need more effective treatments. The initial funding commitment will be $25m.

Go deeper with GlobalData

Premium Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

The partnership will focus on new approaches such as artificial intelligence-based techniques, and aims to encourage pre-clinical development research to boost innovative and effective treatments for the cancer.

Lustgarten Foundation chief scientist David Tuveson said: “The Collective will utilise the breadth and expertise of existing SU2C-Lustgarten Foundation research teams and researchers to support new investigators coming into the field and expand the capacity for additional research.”

“The Collective will utilise the breadth and expertise of existing SU2C-Lustgarten Foundation research teams and researchers to support new investigators coming into the field and expand the capacity for additional research.”

SU2C will provide an additional $10m for research aimed at improving the treatment of multiple myeloma through early detection of precursor conditions, which do not cause symptoms.

Researchers will examine blood samples from about 50,000 people in the US and expect to identify approximately 3,000 with precursor conditions.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

These samples will be used to identify biomarkers and pinpoint those at high risk of disease progression.

The team also intends to develop therapies for multiple myeloma and high-risk smoldering multiple myeloma.

Researchers believe that gaining better insights into the molecular and immune factors associated with disease development, when combined with early detection, can aid the development of new strategies to prevent progression and improve survival.